| Drug ID | DDPD00666 |
|
| Drug Name | Nafarelin | |
| Molecular Weight | 1322.496 | |
| Molecular Formula | C66H83N17O13 | |
| CAS Number | 76932-56-4 | |
| SMILES | CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O | |
| External Links | ||
| DRUGBANK | DB00666 | |
| T3DB | T3D2855 | |
| PubChem Compound | 25077405 | |
| PDR | 2794 | |
| Drugs.com | Drugs.com Drug Page | |
Not Available
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Absorption | 0 | % | 0 | % | PO, oral; | DRUGBANK |
| Bioavailability | 2.8 | % | 2.8(1.2-5.6) | % | inhalation, IH; | DRUGBANK |
| Clearance | 0.0432 | L/h/kg | 0.72 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 0.14 | L/kg | 0.14 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.0 | h | 3 | h | DRUGBANK | Half-life | 3.5 | h | 3.5 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Protein Binding | 80.0 | % | 80 | % | DRUGBANK |
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 1.8 | mg/day | 1800 | mcg/day | intranasal | Synarel | nafarelin acetate | PDR |
| Max dose for adolescents | 1.8 | mg/day | 1800 | mcg/day | intranasal | Synarel | nafarelin acetate | PDR |
| Max dose for adults | 0.4 | mg/day | 400 | mcg/day | subcutaneous injection, SC | Synarel | nafarelin acetate | PDR |
| Max dose for adults | 0.8 | mg/day | 800 | mcg/day | intranasal | Synarel | nafarelin acetate | PDR |